StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com began coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a research report released on Wednesday. The firm issued a sell rating on the stock.

Separately, Alliance Global Partners upped their price objective on shares of Tonix Pharmaceuticals from $6.00 to $11.00 and gave the company a “buy” rating in a research note on Monday, July 22nd.

Tonix Pharmaceuticals Stock Performance

NASDAQ TNXP opened at $0.13 on Wednesday. The company has a debt-to-equity ratio of 0.13, a current ratio of 1.15 and a quick ratio of 0.72. The stock’s 50 day simple moving average is $0.15 and its 200-day simple moving average is $1.41. The company has a market cap of $17.99 million, a PE ratio of 0.00 and a beta of 2.06. Tonix Pharmaceuticals has a 1-year low of $0.12 and a 1-year high of $22.14.

Tonix Pharmaceuticals (NASDAQ:TNXP) last announced its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share for the quarter, beating analysts’ consensus estimates of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 158.64% and a negative net margin of 1,197.86%. The company had revenue of $2.82 million for the quarter, compared to analyst estimates of $2.63 million. As a group, equities research analysts anticipate that Tonix Pharmaceuticals will post -18 EPS for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

A hedge fund recently raised its stake in Tonix Pharmaceuticals stock. Acadian Asset Management LLC lifted its position in Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 335,373 shares of the company’s stock after buying an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned approximately 0.40% of Tonix Pharmaceuticals worth $61,000 at the end of the most recent reporting period. 82.26% of the stock is owned by hedge funds and other institutional investors.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.